CN100502871C - 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用 - Google Patents

巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用 Download PDF

Info

Publication number
CN100502871C
CN100502871C CNB200380104405XA CN200380104405A CN100502871C CN 100502871 C CN100502871 C CN 100502871C CN B200380104405X A CNB200380104405X A CN B200380104405XA CN 200380104405 A CN200380104405 A CN 200380104405A CN 100502871 C CN100502871 C CN 100502871C
Authority
CN
China
Prior art keywords
tremor
treatment
patients
disease
dmmdpb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200380104405XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1717235A (zh
Inventor
丹尼尔·阿龙·莫罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of CN1717235A publication Critical patent/CN1717235A/zh
Application granted granted Critical
Publication of CN100502871C publication Critical patent/CN100502871C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB200380104405XA 2002-12-11 2003-12-11 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用 Expired - Fee Related CN100502871C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43247002P 2002-12-11 2002-12-11
US60/432,470 2002-12-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2009101372903A Division CN101569626B (zh) 2002-12-11 2003-12-11 使用巴比土酸衍生物治疗运动障碍的方法

Publications (2)

Publication Number Publication Date
CN1717235A CN1717235A (zh) 2006-01-04
CN100502871C true CN100502871C (zh) 2009-06-24

Family

ID=32507936

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB200380104405XA Expired - Fee Related CN100502871C (zh) 2002-12-11 2003-12-11 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
CN2009101372903A Expired - Fee Related CN101569626B (zh) 2002-12-11 2003-12-11 使用巴比土酸衍生物治疗运动障碍的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009101372903A Expired - Fee Related CN101569626B (zh) 2002-12-11 2003-12-11 使用巴比土酸衍生物治疗运动障碍的方法

Country Status (17)

Country Link
US (3) US7166610B2 (enExample)
EP (2) EP1569627B1 (enExample)
JP (1) JP4739760B2 (enExample)
CN (2) CN100502871C (enExample)
AR (1) AR042444A1 (enExample)
AT (1) ATE413867T1 (enExample)
AU (2) AU2003302897C1 (enExample)
BR (1) BR0317289A (enExample)
CA (1) CA2505335C (enExample)
CL (1) CL2003002588A1 (enExample)
DE (1) DE60324703D1 (enExample)
ES (1) ES2315569T3 (enExample)
IL (1) IL168853A (enExample)
MX (1) MXPA05006271A (enExample)
PT (1) PT1569627E (enExample)
TW (2) TWI334780B (enExample)
WO (1) WO2004052350A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569626B (zh) * 2002-12-11 2012-02-08 塔罗制药工业有限公司 使用巴比土酸衍生物治疗运动障碍的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates
WO2013038427A1 (en) * 2011-09-12 2013-03-21 Council Of Scientific & Industrial Research ARYLATED β-DICARBOIMYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
IT201700059814A1 (it) * 2017-05-31 2018-12-01 Antonio Costantini Vitamina b1 in alte dosi per uso nel trattamento medico di alcune malattie neurodegenerative sporadiche , di origine genetica e delle cefalee primarie
JP7357432B2 (ja) 2017-10-10 2023-10-06 信越化学工業株式会社 Ｅｕｖ用ペリクルフレーム、ペリクル、ペリクル付露光原版、露光方法、及び半導体の製造方法
JP7787991B2 (ja) * 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039779A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1960170A (en) * 1934-05-22 Cc - phenylethyl - n -
US2119701A (en) 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
US2673205A (en) * 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
DE946804C (de) 1952-02-28 1956-08-09 Emanuel Merck Ohg Verfahren zur Herstellung von schwefelhaltigen Abkoemmlingen der Barbitursaeure
DE1103339B (de) 1959-02-04 1961-03-30 Chemische Werke Radebeul Veb Verfahren zur Herstellung von in 5-Stellung crotylierten, basisch substituierten Barbitursaeure-derivaten
DE1100639B (de) 1959-03-24 1961-03-02 Chemische Werke Radebeul Veb Verfahren zur Herstellung von basisch substituierten Barbitursaeure-derivaten
GB966098A (en) 1959-11-23 1964-08-06 Sapos Sa Barbiturate derivatives
US3930006A (en) * 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
US4046894A (en) * 1968-08-05 1977-09-06 Bristol-Myers Company Certain barbituric acid derivatives used as anticonvulsant agents
US3679683A (en) 1970-05-11 1972-07-25 Exxon Research Engineering Co Barbiturate 3-n-methylene phosphates
US3711607A (en) * 1971-03-17 1973-01-16 Kendall & Co N,n -dihalomethyl phenobarbital for the treatment of convulsions
US3919427A (en) * 1972-06-02 1975-11-11 Kendall & Co Therapeutic compositions containing 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3904627A (en) * 1972-06-02 1975-09-09 Kendall & Co 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3900475A (en) * 1972-06-26 1975-08-19 Kendall & Co Certain phenobarbital salts
US3948896A (en) * 1973-02-28 1976-04-06 The Kendall Company N-mono(alkoxymethyl) phenobarbitals, process therefor and therapeutic composition and method containing same
US4060528A (en) * 1975-10-08 1977-11-29 Janssen Pharmaceutica N.V. Aroyl-substituted phenylmalonic acid derivatives
US4029662A (en) * 1976-04-30 1977-06-14 Bristol-Myers Company Method of making barbituric acid derivatives
DE2622981A1 (de) 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
EP0103233B1 (en) * 1982-08-31 1987-11-25 Daikin Kogyo Co., Ltd. A method to trap the enolate ion of the malonic acid or its derivatives
IL69722A (en) 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4631294A (en) * 1985-07-05 1986-12-23 University E.M., Inc. Treatment of cerebral ischemia with dichloroacetate
IT1196500B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Derivati dell'acido malonico e metodi per la loro sintesi
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
DE4028040A1 (de) 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
US5456851A (en) 1994-04-07 1995-10-10 Johnson & Johnson Consumer Products, Inc. Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
RU2147584C1 (ru) * 1995-10-27 2000-04-20 Американ Цианамид Компани Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов
KR100194535B1 (ko) * 1995-12-27 1999-06-15 우종일 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물
EP0949259B1 (en) * 1996-12-26 2001-06-20 Nikken Chemicals Company, Limited N-hydroxyurea derivatives and medicinal compositions containing the same
US5750766A (en) * 1997-03-18 1998-05-12 American Cyanamid Company Process for the preparation of arylmalonates
US5756815A (en) * 1997-03-18 1998-05-26 American Cyanamid Company Process for the preparation arylamalonates
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CA2317008C (en) 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
DE69906960T2 (de) * 1998-05-08 2004-01-29 Smithkline Beecham Plc Phenylurea und phenylthio urea derivate
IL139884A0 (en) 1998-05-26 2002-02-10 Natural Drug Sciences Llc N-substituted derivatives of 5-oximinobarbituric acid
US6156925A (en) * 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
AU2001280778B2 (en) * 2000-07-26 2004-09-02 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CN1291720C (zh) 2002-01-30 2006-12-27 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
AR042444A1 (es) 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039779A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACUTE EFFECTS OF BARBITURATES INPARKINSON'SDISEASE. Gunnar STURFELT, ET AL.ACTA MED SCAND,Vol.201. 1977 *
DOUBLE-BLIND COMPARISON OF PRIMIDONE ANDPHENOBARBITAL IN ESSENTIAL TREMOR. Enrico SASSO, ET AL.NEUROLOGY,Vol.38. 1988 *
Effects of striatal injections of GABAA receptor agonists andantagonists in a genetic animal model of paroxysmal dystonia. MELANIE HAMANN, ET AL.EUROPEAN JOURNAL OF PHARMACOLOGY,Vol.443. 2002 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569626B (zh) * 2002-12-11 2012-02-08 塔罗制药工业有限公司 使用巴比土酸衍生物治疗运动障碍的方法

Also Published As

Publication number Publication date
MXPA05006271A (es) 2006-01-30
DE60324703D1 (de) 2008-12-24
ES2315569T3 (es) 2009-04-01
TW200418481A (en) 2004-10-01
AU2010200787A1 (en) 2010-03-25
CA2505335A1 (en) 2004-06-24
EP1569627A2 (en) 2005-09-07
EP1569627B1 (en) 2008-11-12
AU2003302897A1 (en) 2004-06-30
US7166610B2 (en) 2007-01-23
JP2006510659A (ja) 2006-03-30
JP4739760B2 (ja) 2011-08-03
US20040186120A1 (en) 2004-09-23
US7776871B2 (en) 2010-08-17
CN101569626B (zh) 2012-02-08
CN101569626A (zh) 2009-11-04
WO2004052350A2 (en) 2004-06-24
WO2004052350A3 (en) 2004-09-23
US20070072886A1 (en) 2007-03-29
TW200822927A (en) 2008-06-01
ATE413867T1 (de) 2008-11-15
CA2505335C (en) 2013-09-10
AU2003302897C1 (en) 2010-07-08
AU2003302897B2 (en) 2009-12-03
CL2003002588A1 (es) 2005-01-07
US20100311771A1 (en) 2010-12-09
CN1717235A (zh) 2006-01-04
PT1569627E (pt) 2009-01-20
AR042444A1 (es) 2005-06-22
EP2156839A1 (en) 2010-02-24
BR0317289A (pt) 2005-11-08
IL168853A (en) 2011-07-31
US8314115B2 (en) 2012-11-20
TWI334780B (en) 2010-12-21

Similar Documents

Publication Publication Date Title
US8314115B2 (en) Method of treating movement disorders using barbituric acid derivatives
US7030108B2 (en) Combating Parkinson's disease-related movement disorder
EP0209689B1 (en) Use of tetrahydrobiopterins in the preparation of a medicament for the treatment of infantile autism
KR20150002640A (ko) 파킨슨병을 치료하기 위한 신규의 치료적 접근법
US20020068692A1 (en) Method for the treatment of neurological or neuropsychiatric disorders
JPH0733332B2 (ja) 痴呆症状改善・治療剤
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
AU2003267557B2 (en) Treatment of dyskinesia
EP3556364B1 (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
EP3854392A1 (en) Use of carbamate compound for prevention, alleviation, or treatment of concurrent seizures
US20080242657A1 (en) Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
HK1143306A (en) Method of treating movement disorders using barbituric acid derivatives
JPH10279497A (ja) β−アミノ酸吸収抑制剤
JPWO1999030715A1 (ja) 睡眠障害の予防・治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090624

Termination date: 20131211